menu
    • menu
    [{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"University of Maryland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"ENA Respiratory \/ University of Maryland","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ University of Maryland"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Blue Knight","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Blue Knight","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Blue Knight"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ US Department of Defense"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"COPD Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ COPD Foundation","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ COPD Foundation"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ US Department of Defense"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Flu Lab","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Flu Lab","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Flu Lab"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Brandon Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Brandon Capital","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Brandon Capital"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Gates Foundation | Flu Lab | Brandon Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Gates Foundation | Flu Lab | Brandon Capital","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Gates Foundation | Flu Lab | Brandon Capital"},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"INNA-051","moa":"Toll-like-2\/Toll-like-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ENA Respiratory","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"ENA Respiratory \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ENA Respiratory \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by ENA Respiratory

    Menu

    ENA Respiratory

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            INNA-051 Preventive Study for Respiratory Illness in Healthy Adults

                            Details : INNA-051 is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Respiratory Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 30, 2025

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Gates Foundation | Flu Lab | Brandon Capital

                            Deal Size : $22.4 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Ena Respiratory Raises US$22.4M for INNA-051 Nasal Spray Phase II Development

                            Details : The Series B financing for INNA-051, a small molecule product targeting Toll-like-2/Toll-like-6 receptor, will advance asthma treatment.

                            Product Name : INNA-051

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 22, 2025

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Gates Foundation | Flu Lab | Brandon Capital

                            Deal Size : $22.4 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : University of Maryland

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ENA and Maryland Launch Phase 2 Study for INNA-051 Antiviral Therapy

                            Details : The partnership aims to advance the company’s lead product, INNA-051, is being developed as a convenient, once-a-week nasal dry powder product to reduce the impact of viral respiratory infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 09, 2025

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : University of Maryland

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Flu Lab

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ENA Respiratory gets $5M from Flu Lab for INNA-051 Intranasal Antiviral

                            Details : The financing aims to fund the clinical development of the company’s lead product, INNA-051, which is being developed for treating Influenza Prophylaxis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 10, 2025

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Flu Lab

                            Deal Size : $5.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ENA Respiratory Completes Phase Ib Dosing of INNA-051 in Older Adults for Antiviral Study

                            Details : INNA-051 is a TLR2/6 agonist, small molecule drug candidate in development as an innate immune modulator, delivered using a nasal spray. It is being evaluated for viral respiratory infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2025

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ENA Respiratory Advances Phase Ib Trial of INNA-051 for Intranasal COVID-19 Treatment

                            Details : INNA-051 is a TLR2/6 agonist, small molecule drug candidate in development as an innate immune modulator, delivered using a nasal spray. It is being evaluated for Influenza & COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 27, 2024

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ENA Respiratory Receives FDA IND Clearance for Intranasal INNA-051

                            Details : INNA-051 is a TLR2/6 agonist, small molecule drug candidate in development as an innate immune modulator, delivered using a nasal spray. It is being evaluated for the treatment of Influenza.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 29, 2024

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerat...

                            Details : INNA-051 is a potent TLR2/6 agonist that is delivered using a convenient nasal spray to target the preferential site of initial replication of viral respiratory infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 11, 2023

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : US Department of Defense

                            Deal Size : $8.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Prog...

                            Details : The funding will support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator for the prevention of complications associated with respiratory viral infections in at-risk populations.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 29, 2023

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : US Department of Defense

                            Deal Size : $8.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed

                            ENA Respiratory

                            Australia arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study

                            Details : INNA-051 is a broad-spectrum antiviral immunomodulatory nasal spray under clinical development for pre- and post-exposure prophylaxis of respiratory viral infections in populations at risk of severe complications.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 14, 2023

                            Lead Product(s) : INNA-051

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth